Biotech | April 06, 2026
Enveda’s experimental oral therapy shows breakthrough results in atopic dermatitis trial
Safety was equally impressive. ENV-294 was well tolerated
Safety was equally impressive. ENV-294 was well tolerated
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
With more than two decades of experience, he brings deep expertise in sales, marketing, business transformation, and strategic leadership
Board approves five-year appointment, subject to shareholder nod through postal ballot
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
Subscribe To Our Newsletter & Stay Updated
